Can Dynamic Susceptibility Contrast Perfusion Imaging be Utilized to Detect Isocitrate Dehydrogenase Gene Mutation in...

Area of Science:

• Neuroimaging
• Oncology
• Molecular Diagnostics

Background:

• Gliomas are primary brain tumors with distinct molecular subtypes.
• Isocitrate dehydrogenase (IDH) gene mutations are key prognostic and predictive biomarkers in gliomas.
• Accurate noninvasive detection of IDH mutation status is crucial for guiding treatment strategies.

Purpose of the Study:

• To evaluate the efficacy of dynamic susceptibility contrast perfusion imaging (DSC-PI) in identifying IDH gene mutations in gliomas.
• To compare perfusion parameters between IDH-mutant and IDH wild-type gliomas.

Main Methods:

• Retrospective analysis of preoperative DSC-PI data from 2015-2019.
• Acquisition of MRI data using a 1.5-T scanner.
• Calculation of maximum relative cerebral blood volume (rCBVmax) and percentage signal recovery (PSR) values from tumor cores.
• Statistical comparison of perfusion parameters between IDH-mutant and wild-type gliomas using receiver operating characteristic (ROC) curve analysis.

Main Results:

• Significant differences in rCBVmax and PSR values were observed between IDH-mutant and wild-type gliomas (p < 0.01).
• The study included 32 female and 47 male patients aged 21-76 years (mean 50.7 ± 15 years).

Conclusions:

• DSC-PI derived parameters, specifically rCBVmax and PSR, show potential for noninvasive IDH mutation status detection in gliomas.
• Percentage signal recovery (PSR) demonstrated superior reliability in differentiating IDH-mutant from wild-type gliomas.